IP7e
CAS No. 500164-74-9
IP7e( IP 7e | IP-7e | isoxazolo-pyridinone 7e )
Catalog No. M27887 CAS No. 500164-74-9
IP7e is a Nurr1 activator with an EC50 value of 3.9 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 120 | In Stock |
|
| 5MG | 107 | In Stock |
|
| 10MG | 163 | In Stock |
|
| 25MG | 376 | In Stock |
|
| 50MG | 604 | In Stock |
|
| 100MG | 918 | In Stock |
|
| 200MG | 1283 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIP7e
-
NoteResearch use only, not for human use.
-
Brief DescriptionIP7e is a Nurr1 activator with an EC50 value of 3.9 nM.
-
DescriptionIP7e is a Nurr1 activator with an EC50 value of 3.9 nM.(In Vivo):IP7e(10 mg/kg) attenuates inflammation and neurodegeneration in spinal cords of EAE mice by an NF-kB pathway-dependent process. IP7e preventive treatment reduces the incidence and the severity of an MS murine model, i.e. experimental autoimmune encephalomyelitis (EAE).
-
In Vitro——
-
In VivoIP7e (Isoxazolo-pyridinone 7e; 10 mg/kg; oral gavage; twice a day) preventive treatment reduces the incidence and the severity of a MS murine model, i.e. experimental autoimmune encephalomyelitis (EAE). IP7e attenuates inflammation and neurodegeneration in spinal cords of EAE mice by an NF-kB pathway-dependent process. Animal Model:Female C57BL/6J mice (6-8 week-old) with experimental autoimmune encephalomyelitis (EAE).Dosage:10 mg/kgAdministration:Oral gavage; twice a day; preventive administration (before the disease onset) from 7 to 23 d.p.i. and therapeutic (after the disease onset) from 21 to 36 d.p.i. Result:Preventive administration delayed the onset and reduces the incidence and severity of EAE, and decreased neuroinflammatory and histopathological alterations in the spinal cord of treated EAE mice. On the contrary, the course of EAE was not influenced by the therapeutic administration.
-
SynonymsIP 7e | IP-7e | isoxazolo-pyridinone 7e
-
PathwayOthers
-
TargetOther Targets
-
RecptorACMSD
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number500164-74-9
-
Formula Weight390.439
-
Molecular FormulaC23H22N2O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (256.13 mM)
-
SMILESCOCCOCc1ccc(cc1)-c1cc2onc(-c3ccccc3)c2c(=O)n1C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Pellicciari R, et al. α-Amino-β-carboxymuconate-ε-semialdehyde Decarboxylase (ACMSD) Inhibitors as Novel Modulators of De Novo Nicotinamide Adenine Dinucleotide (NAD+) Biosynthesis. J Med Chem. 2018 Feb 8;61(3):745-759.
molnova catalog
related products
-
GAK inhibitor 49
GAK inhibitor 49 is a highly selective and ATP-competitive cyclin G associated kinase (GAK) inhibitor (IC50: 56 nM; Ki: 0.54 nM ).
-
Orexin B, human
Orexin B, human is an endogenous agonist at Orexin receptor with Kis of 420 and 36 nM for OX1 and OX2, respectively. Orexin B is a hypothalamatic neuropeptide stimulating food intake in rats.
-
Vadocaine
Vadocaine (Vadocaina) is a novel analgesic compound for local anaesthesia and can be used to study the central nervous system and cardiovascular system.
Cart
sales@molnova.com